Evaluation of Dosimetric Parameters and Disease Response After 125Iodine Transperineal Brachytherapy for Low- and Intermediate-Risk Prostate Cancer
William Morris(Vanderbilt University), Ryan Woods, Robert L. Harrison(Agricultural Research Service), Eric Berthelet(University of British Columbia), William Kwa, Ingrid Spadinger, Joe Bucci(St George Hospital), Tom Pickles, Mira Keyes(BC Cancer Agency), Howard Pai(BC Cancer Agency), Vince Lapointe(BC Cancer Agency), Michael McKenzie(Provincial Health Services Authority), David A. Palma(Western University), Alex Agranovich(BC Cancer Agency), Winkle Kwan, Violet Racz, Jonn Wu, Mitchell Liu
International Journal of Radiation Oncology*Biology*Physics
December 3, 2008
Cited by 64
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k